BC Cancer Protocol Summary For Tamoxifen For Patients With Recurrent Desmoid Tumors/Aggressive Fibromatosis

Protocol Code
SATAM

Tumour Group
Sarcoma

Contact Physician
Dr. Christine Simmons

ELIGIBILITY/TESTS:
Recurrent desmoid tumor or aggressive fibromatosis patients for whom other treatment modalities are not available.

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>tamoxifen</td>
<td>20 mg BID</td>
<td>PO</td>
</tr>
</tbody>
</table>

DOSE MODIFICATIONS:
Discontinue drug for severe side effects OR obvious progression of disease OR stabilisation of disease for six months.

PRECAUTIONS:
Women: hot flushes, vaginitis
Men: decrease in libido
Both: phlebitis, rare retinitis (reversible)
Allergy, rash, nausea and vomiting are very rare. In sarcoma patients any observed hematologic abnormality would be idiosyncratic and routine CBC’s are not recommended.

MONITORING:
CT/MR every 3-6 months to monitor progress, UNLESS obvious clinical progression, then clinical discretion re: further imaging.

Call Dr. Christine Simmons or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.